ALIF_B: Q2 2024 saw strong growth, higher profitability, and improved cash flow, supporting a positive outlook

About this update from Addlife Ab Class B

AddLife delivered 8% sales growth and a 21% EBITA increase in Q2 2024, with both Labtech and Medtech segments performing strongly. Improved cash flow, reduced debt, and the Bonsai Lab acquisition support a positive outlook for the rest of the year.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Addlife Ab Class B